Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)
Taiwan
· Delayed Price · Currency is TWD 76.00
-0.20 (-0.26%)
Aug 15, 2025, 2:31 PM CST
Foresee Pharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -1,420 | -1,081 | -1,036 | -472.64 | -569.27 | -510.71 | Upgrade
|
| Depreciation & Amortization | 76.52 | 79.1 | 73.45 | 50.93 | 51.16 | 48.71 | Upgrade
|
| Other Amortization | 1.42 | 1.42 | 0.18 | 0.22 | 0.32 | 0.77 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0.03 | 0.2 | 0.31 | 0.13 | 0.06 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 1.16 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -0.29 | -0.8 | -0.52 | Upgrade
|
| Stock-Based Compensation | 59.91 | 49.82 | 50.77 | 40.18 | 23.92 | 22.89 | Upgrade
|
| Other Operating Activities | 2.29 | -3.68 | 0.5 | 0.69 | -9.42 | 4.56 | Upgrade
|
| Change in Accounts Receivable | -10.24 | 33.58 | -49.64 | -16.27 | - | 0.01 | Upgrade
|
| Change in Inventory | -8.76 | -57.08 | 49.61 | -151.53 | 40.1 | 32.82 | Upgrade
|
| Change in Accounts Payable | 9.68 | 52.29 | -10.72 | 22.85 | - | 7.12 | Upgrade
|
| Change in Unearned Revenue | -117.03 | -114.5 | -1.01 | -1.8 | 160.76 | 23.77 | Upgrade
|
| Change in Other Net Operating Assets | 43.8 | -133.67 | 35.41 | -4.79 | 34.76 | -1.27 | Upgrade
|
| Operating Cash Flow | -1,362 | -1,174 | -887.56 | -233.22 | -213.33 | -674.8 | Upgrade
|
| Capital Expenditures | -120.3 | -149.59 | -46.28 | -58.07 | -6.86 | -12.79 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.21 | 0.23 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -12.04 | -6.36 | - | - | -0.54 | -15.4 | Upgrade
|
| Investment in Securities | 25 | 267.5 | -249 | 100 | 25 | -125 | Upgrade
|
| Other Investing Activities | 0.3 | 1.06 | -1.03 | -1.23 | 0.02 | 0.15 | Upgrade
|
| Investing Cash Flow | -107.04 | 112.82 | -296.08 | 40.7 | 17.62 | -153.03 | Upgrade
|
| Short-Term Debt Issued | - | 800 | 300 | - | - | 40 | Upgrade
|
| Long-Term Debt Issued | - | 100 | - | - | - | 84.53 | Upgrade
|
| Total Debt Issued | 700 | 900 | 300 | - | - | 124.53 | Upgrade
|
| Short-Term Debt Repaid | - | -850 | -100 | - | -30.07 | -9.93 | Upgrade
|
| Long-Term Debt Repaid | - | -17.09 | -15.52 | -11.35 | -84.1 | -10.63 | Upgrade
|
| Total Debt Repaid | -667.89 | -867.09 | -115.52 | -11.35 | -114.17 | -20.56 | Upgrade
|
| Net Debt Issued (Repaid) | 32.12 | 32.91 | 184.48 | -11.35 | -114.17 | 103.97 | Upgrade
|
| Issuance of Common Stock | 1,372 | 1,378 | 1,319 | 14.21 | 38.43 | 1,425 | Upgrade
|
| Financing Cash Flow | 1,404 | 1,411 | 1,504 | 2.86 | -75.74 | 1,529 | Upgrade
|
| Foreign Exchange Rate Adjustments | -40.58 | 8 | -0.09 | 7.73 | -2.23 | -3.71 | Upgrade
|
| Net Cash Flow | -105.5 | 357.62 | 320.17 | -181.93 | -273.68 | 697.1 | Upgrade
|
| Free Cash Flow | -1,482 | -1,323 | -933.84 | -291.29 | -220.19 | -687.58 | Upgrade
|
| Free Cash Flow Margin | -334.81% | -316.07% | -478.80% | -96.61% | -97.42% | -298.38% | Upgrade
|
| Free Cash Flow Per Share | -10.12 | -9.64 | -7.34 | -2.47 | -1.88 | -6.78 | Upgrade
|
| Cash Interest Paid | 6.47 | 6.47 | 2.68 | 0.4 | 0.76 | 0.92 | Upgrade
|
| Cash Income Tax Paid | 51.71 | 51.71 | 46.01 | 29.01 | 41.66 | 26.65 | Upgrade
|
| Levered Free Cash Flow | -840.25 | -753.85 | -616.79 | -402.03 | -236.28 | -259.81 | Upgrade
|
| Unlevered Free Cash Flow | -836.74 | -749.65 | -615.01 | -401.78 | -235.85 | -259.19 | Upgrade
|
| Change in Working Capital | -82.55 | -219.37 | 23.64 | 146.23 | 290.62 | -240.55 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.